Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Effient Review Delayed More By Management Issues Than Clinical Disputes

Executive Summary

Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate

You may also be interested in...



Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage

John Lechleiter faced a tough crowd on Dec. 10: three months after announcing a reorganization of Eli Lilly's R&D apparatus and global cutbacks, the drug maker's CEO came to New York to explain to Wall Street analysts how he planned to cope with a massive loss of revenue due to begin in just two years as patents expire on several best-selling medicines

Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage

John Lechleiter faced a tough crowd on Dec. 10: three months after announcing a reorganization of Eli Lilly's R&D apparatus and global cutbacks, the drug maker's CEO came to New York to explain to Wall Street analysts how he planned to cope with a massive loss of revenue due to begin in just two years as patents expire on several best-selling medicines

AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?

The comparator in AstraZeneca's PLATO trial for its antiplatelet candidate Brilinta (ticagrelor) was clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) but the real test for the product, should it reach the market, may be against Eli Lilly/Daiichi Sankyo's recently approved Effient (prasugrel)

Related Content

Topics

UsernamePublicRestriction

Register

PS051646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel